グレーブス眼症:治療薬開発パイプライン分析

【英語タイトル】Graves' Ophthalmopathy - Pipeline Review, H2 2017

Global Markets Directが出版した調査資料(GMDHC10031IDB)・商品コード:GMDHC10031IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2017年12月29日
・ページ数:33
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界におけるグレーブス眼症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・グレーブス眼症の概要
・グレーブス眼症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・グレーブス眼症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・グレーブス眼症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・グレーブス眼症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Graves’ Ophthalmopathy – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Graves’ Ophthalmopathy – Pipeline Review, H2 2017, provides an overview of the Graves’ Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Graves’ Ophthalmopathy – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Graves’ Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves’ Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves’ Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.

Graves’ Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves’ Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves’ Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves’ Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves’ Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves’ Ophthalmopathy (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves’ Ophthalmopathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves’ Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Graves’ Ophthalmopathy – Overview
Graves’ Ophthalmopathy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves’ Ophthalmopathy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves’ Ophthalmopathy – Companies Involved in Therapeutics Development
Enceladus Pharmaceuticals BV
Genmab A/S
Novartis AG
Yuhan Corp
Graves’ Ophthalmopathy – Drug Profiles
pasireotide ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisolone sodium phosphate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teprotumumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-BIO – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-NCE3 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves’ Ophthalmopathy – Dormant Projects
Graves’ Ophthalmopathy – Product Development Milestones
Featured News & Press Releases
Oct 25, 2017: Horizon Pharma Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease
Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease
Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Graves' Ophthalmopathy, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Graves' Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, H2 2017
Graves' Ophthalmopathy - Pipeline by Genmab A/S, H2 2017
Graves' Ophthalmopathy - Pipeline by Novartis AG, H2 2017
Graves' Ophthalmopathy - Pipeline by Yuhan Corp, H2 2017
Graves' Ophthalmopathy - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Graves' Ophthalmopathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

グレーブス眼症

★調査レポート[グレーブス眼症:治療薬開発パイプライン分析] (コード:GMDHC10031IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[グレーブス眼症:治療薬開発パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆